# Depatuxizumab mafodotin

Source: https://onco.cc/drugs/depatuxizumab-mafodotin/  
OnCo record `depatuxizumab-mafodotin` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Depatuxizumab mafodotin carried a cell-killing payload to glioblastomas with extra copies of the EGFR gene. It caused serious eye problems and, in the phase 3 INTELLANCE-1 trial, did not help patients live longer, so development stopped in 2019.

## Summary

Depatuxizumab mafodotin (ABT-414) was AbbVie's antibody-drug conjugate for EGFR-amplified glioblastoma, present in roughly 40 to 50 percent of cases. The antibody binds EGFR only where it is overexpressed or mutated, sparing normal tissue, and delivers monomethyl auristatin F. It was given intravenously every two weeks with radiotherapy and temozolomide.

INTELLANCE-1 (RTOG 3508), a phase 3 trial in newly diagnosed EGFR-amplified glioblastoma, found no improvement in overall survival at its 2019 interim analysis and enrolment stopped; INTELLANCE-2, in recurrent disease, showed only a late trend. Corneal toxicity with blurred vision affected most patients. The glioblastoma page lists it among the major systemic trials that failed after temozolomide.

## Fields

- Kind: Treatment
- Status: negative
- Last checked: 2026-09-17
- Also known as: ABT-414; Depatux-M
- Tags: subtype-drugs-wave
- Code: ABT-414
- Modality: EGFR-targeted antibody-drug conjugate (MMAF payload)
- Mechanism: An antibody that binds a conformational EGFR epitope exposed on tumours with EGFR amplification or the EGFRvIII mutant, linked to the microtubule toxin monomethyl auristatin F; the conjugate is internalised and the payload stops cell division.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Depatuxizumab_mafodotin
- Wikipedia: https://en.wikipedia.org/wiki/Depatuxizumab_mafodotin

## Connected records

- drugs: [Temozolomide](https://onco.cc/drugs/temozolomide/)
- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [Tubulin (microtubules)](https://onco.cc/targets/tubulin/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)
- trials: [INTELLANCE-1](https://onco.cc/trials/intellance-1/)

---
JSON: https://onco.cc/api/v1/entities/depatuxizumab-mafodotin.json